Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.

Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC. · 2014

Read Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. by Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4180007.txt.

Introduction

Eric L. Simpson, Hywel C. Williams, and eight co-authors tested a simple idea for preventing eczema in the Journal of Allergy and Clinical Immunology in 2014. Atopic dermatitis, the itchy skin condition, often starts in infancy, and faulty skin barrier may be an early trigger. If cream could shore up the barrier from birth, the disease might never start.

The trial enrolled 124 newborns at high risk in the United States and the United Kingdom. Parents in one group applied moisturizer over the baby's whole body daily from the first three weeks of life; the other group used none. Families found the routine easy to accept. By six months the cream group showed a clear drop in eczema cases, with risk cut by about half. A bigger trial was the next step.

Catalog record

CREATORSimpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4180007

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention By Eric L Simpson, Joanne R Chalmers, Jon M Hanifin, Kim S Thomas, Michael J Cork, WH Irwin McLean, Sara J Brown, Zunqiu Chen, Yiyi Chen, Hywel C Williams Published in: The Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2014.08.005 ABSTRACT Abstract Background Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization. Objective Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates. Methods We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator. Results Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups. Conclusion The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases. Key words: Atopic dermatitis, eczema, skin barrier, prevention, emollients Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence.1, 2 Children with atopic dermatitis experience intractable itch along with inflamed, cracked, and often infected skin lesions. The onset of atopic dermatitis in childhood often heralds the development of subsequent allergic disorders, such as food allergy, asthma, and allergic rhinitis (the atopic march), as well as neurodevelopmental disorders.3, 4 Development of an effective prevention strategy for atopic dermatitis and associated allergic disease would represent a major public health breakthrough. Atopic dermatitis has been historically classified as an allergic disease, given its association with IgE-mediated diseases, such as food allergy. Prevention trials to date have primarily focused on allergen avoidance. Unfortunately, the results of these studies have been largely disappointing or inconsistent, and no single accepted prevention strategy has emerged.5 Recent advances in cutaneous biology suggest epidermal defects might be a key initiator of atopic dermatitis and possibly allergic sensitization.6, 7, 8 Skin barrier dysfunction is now recognized as central to the initiation and progression of atopic dermatitis. These new findings create an opportunity for the development of novel prevention strategies focusing on the skin barrier. We hypothesize that enhancement of a defective skin barrier early in life might prevent or delay the onset of atopic dermatitis. Emollients provide a safe and effective method of skin barrier enhancement because they provide the skin with a source of exogenous lipids, improving its barrier properties.9, 10, 11 The results of a previous case-control study and open-label trial suggest the use of bland emollients from birth might protect against the onset of skin inflammation in neonates.12, 13 The objective for this study was to test the hypothesis that emollient therapy from birth represents a safe, feasible, and efficacious approach to the prevention of atopic dermatitis (Fig 1). [Figure: Skin barrier protection might prevent atopic dermatitis development. FLG, Filaggrin.] METHODS Study design This was a multicenter, multinational, 2-arm parallel-group, assessor-blind, randomized (1:1) controlled pilot trial of 6 months' duration. The intervention started within 3 weeks of birth. Participants Infants at high risk of eczema, which was defined as having a parent or full sibling who has (or had) physician-diagnosed atopic dermatitis, asthma, or allergic rhinitis, were included. The strongest and most established risk factor for atopic dermatitis is a family history of atopic disease.14, 15 Thus to qualify for this study, neonates had to have had 1 first-degree relative with a history of allergic rhinitis, asthma, or atopic dermatitis. Between 25% and 40% of children with a family history of atopic disease have atopic dermatitis in the first year of life, with some reports putting the risk at greater than 60%.16 Infants needed to be in overall good health, and the mother needed to be at least 16 years of age at delivery and capable of providing informed consent. If mothers had taken Lactobacillus rhamnosus supplements during pregnancy, their infants were excluded. Infants were excluded if they were born before 37 weeks' gestation or if they had a major congenital anomaly, hydrops fetalis, an immunodeficiency syndrome, a severe genetic skin disorder, or a serious skin condition that would make the use of emollients inadvisable. Intervention Parents in the intervention group were offered a choice of 3 emollients of different viscosities (an oil, a cream/gel, or an ointment) that had been selected based on previous data regarding their safety, tolerability, or barrier-protective qualities.17, 18, 19, 20, 21, 22 In the United Kingdom emollient choices were sunflower seed oil (William Hodgson and Co, Congleton, United Kingdom), Doublebase Gel (Dermal Laboratories, Hitchin, United Kingdom), and liquid paraffin 50% in white soft paraffin. In the United States parents were offered the same sunflower seed oil as used in the United Kingdom, Cetaphil Cream (Galderma Laboratories, Fort Worth, Tex), or Aquaphor Healing Ointment (Beiersdorf, Chester, Ohio). We used sunflower seed oil with a high ratio of linoleic/oleic acid to optimize the positive skin barrier effects.23 None of the emollients offered contain sodium lauryl sulfate because this emulsifier has been shown to adversely affect the skin barrier.24 Parents were asked to apply the emollient to the baby's entire body surface, with the exception of the scalp, starting as soon as possible after birth (within a maximum of 3 weeks) and continuing until the infant was 6 months of age. Both the intervention and control groups were given an infant skin care advice booklet, which reflected current guidelines.25 Parents are advised (1) to avoid soap and bubble bath; (2) use a mild, fragrance-free synthetic cleanser designed specifically for babies; (3) avoid bath oils and additives; (4) use a mild, fragrance-free shampoo designed specifically for babies and avoid washing the suds over the baby's body; and (5) avoid using baby wipes, where possible. Outcomes The primary purpose of this trial was to determine the feasibility of this approach for atopic dermatitis prevention in preparation for larger trials. Thus the primary

Read the complete text